###begin article-title 0
###xml 91 92 88 89 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 107 115 <span type="species:ncbi:9606">patients</span>
Bronchial hyper-responsiveness, subepithelial fibrosis, and transforming growth factor-beta1 expression in patients with long-standing and recently diagnosed asthma
###end article-title 0
###begin title 1
Introduction:
###end title 1
###begin p 2
Chronic inflammation in asthmatic airways leads to bronchial hyper-responsiveness (BHR) and the development of structural changes. Important features of remodeling include the formation of subepithelial fibrosis due to increased collagen deposition in the reticular basement membrane. Transforming growth factor (TGF)-beta might be a central mediator of tissue fibrosis and remodeling.
###end p 2
###begin title 3
Materials and Methods:
###end title 3
###begin p 4
###xml 77 78 74 75 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 107 115 <span type="species:ncbi:9606">patients</span>
###xml 180 188 <span type="species:ncbi:9606">patients</span>
Immunohistochemistry was used to measure collagen III deposition and TGF-beta1 expression in biopsies from patients with long-standing asthma treated with inhaled corticosteroids, patients with recently diagnosed asthma, and control subjects. Computer-assisted image analysis was used to evaluate total basement membrane (TBM) thickness.
###end p 4
###begin title 5
Results:
###end title 5
###begin p 6
###xml 378 379 375 376 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 254 262 <span type="species:ncbi:9606">patients</span>
Asthmatics, particularly those with long-standing asthma, had thicker TBMs than healthy subjects. Collagen III deposition was comparable in the studied groups. BHR was not correlated with features of mucosal inflammation and was lower in steroid-treated patients with long-standing asthma than in subjects with newly diagnosed asthma untreated with steroids. Epithelial TGF-beta1 expression negatively correlated with collagen III deposition and TBM thickness.
###end p 6
###begin title 7
Conclusions:
###end title 7
###begin p 8
###xml 427 428 424 425 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
The study showed that TBM thickness, but not collagen III deposition, could be a differentiating marker of asthmatics of different disease duration and treatment. The lack of correlation between BHR and features of mucosal inflammation suggests the complexity of BHR development. Corticosteroids can reduce BHR in asthmatics, but it seems to be less effective in reducing subepithelial fibrosis. The role of epithelial TGF-beta1 needs to be further investigated since the possibility that it plays a protective and anti-inflammatory role in asthmatic airways cannot be excluded.
###end p 8
###begin title 9
Keywords:
###end title 9
###begin title 10
Introduction
###end title 10
###begin p 11
###xml 665 667 665 667 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR16">16</xref>
###xml 1078 1080 1078 1080 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR29">29</xref>
###xml 1905 1907 1896 1898 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR21">21</xref>
###xml 2169 2170 2154 2155 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 2185 2193 <span type="species:ncbi:9606">patients</span>
Airway inflammation and bronchial hyper-responsiveness (BHR) are the hallmarks of asthma. The inflammatory changes are regarded as a key factor in BHR; however, the relationships between inflammation markers and BHR are not clear, with comparable numbers of reports showing or denying such relationships. Structural changes in the airways are thought to be involved in the development of BHR, particularly in long-standing disease, but the relationship between remodeling features and BHR needs to be further investigated. Impaired functioning of the hypothetical epithelial-mesenchymal trophic unit is thought to play an important role in remodeling pathogenesis [16]. The process of the development of structural changes is thought to be responsible for the irreversible airway obstruction. One of the most prominent histopathological features of remodeling is subepithelial fibrosis due to the deposition of a number of extracellular matrix (ECM) proteins, including collagens I, III, and V, fibronectin, tenascin, and proteoglycans in the reticular basement membrane (RBM) [29]. Although these features are well recognized, the mechanisms leading to remodeling and the effect of therapy on preventing or reversing these changes are not well understood. A number of different cells and mediators are involved in airway inflammation and remodeling, forming a complex network of multidirectional reactions. It has been postulated that transforming growth factor (TGF)-beta is one of the important mediators involved in allergic inflammation and remodeling. It is thought to be involved in the downregulation of activated inflammatory cells, tissue differentiation, and wound healing. In the airways, TGF-beta is found in various cell types, including epithelial cells and inflammatory cells beneath the basement membrane. There is speculation about various TGF-beta functions at its different locations [21]. There are also contradictory data as to the distribution of TGF-beta in the airways of asthmatics. All these discrepancies were reasons to carry out the present study. We investigated BHR, subepithelial fibrosis, features of mucosal inflammation, and TGF-beta1 expression in patients with different asthma durations and different applied treatments.
###end p 11
###begin title 12
Materials and Methods
###end title 12
###begin title 13
Subjects
###end title 13
###begin p 14
###xml 132 133 132 133 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 521 522 521 522 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 695 702 695 702 <label xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Table 1</label>
###xml 702 726 702 726 <p xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" textid="15">Subjects&#8217; characteristic</p>
###xml 702 726 702 726 <caption xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="15">Subjects&#8217; characteristic</p></caption>
###xml 726 726 726 726 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 726 740 726 740 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">LSA group n=16</td>
###xml 740 754 740 754 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">RDA group n=18</td>
###xml 754 767 754 767 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Controls n=13</td>
###xml 726 767 726 767 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td/><td>LSA group n=16</td><td>RDA group n=18</td><td>Controls n=13</td></tr>
###xml 767 779 767 779 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Age (years)*</td>
###xml 779 792 779 790 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">49.10&#177;15.50</td>
###xml 792 803 790 799 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">41.6&#177;13.5</td>
###xml 803 815 799 809 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">46.92&#177;14.7</td>
###xml 767 815 767 809 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>Age (years)*</td><td>49.10&#177;15.50</td><td>41.6&#177;13.5</td><td>46.92&#177;14.7</td></tr>
###xml 815 823 809 817 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Sex: F/M</td>
###xml 823 827 817 821 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">15/1</td>
###xml 827 831 821 825 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">17/1</td>
###xml 831 835 825 829 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">10/3</td>
###xml 815 835 809 829 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>Sex: F/M</td><td>15/1</td><td>17/1</td><td>10/3</td></tr>
###xml 835 858 829 852 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Asthma duration (years)</td>
###xml 858 871 852 863 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">14.50&#177;12.70</td>
###xml 871 880 863 870 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1.7&#177;1.3</td>
###xml 880 881 870 871 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#8212;</td>
###xml 835 881 829 871 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>Asthma duration (years)</td><td>14.50&#177;12.70</td><td>1.7&#177;1.3</td><td>&#8212;</td></tr>
###xml 881 897 871 887 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Asthma severity:</td>
###xml 897 897 887 887 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 897 897 887 887 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 897 897 887 887 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 881 897 871 887 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>Asthma severity:</td><td/><td/><td/></tr>
###xml 897 901 887 891 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">mild</td>
###xml 901 907 891 897 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">8(50%)</td>
###xml 907 916 897 906 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">16(88.8%)</td>
###xml 916 917 906 907 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#8212;</td>
###xml 897 917 887 907 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>mild</td><td>8(50%)</td><td>16(88.8%)</td><td>&#8212;</td></tr>
###xml 917 925 907 915 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">moderate</td>
###xml 925 933 915 923 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">5(31.2%)</td>
###xml 933 941 923 931 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">2(11.1%)</td>
###xml 941 942 931 932 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#8212;</td>
###xml 917 942 907 932 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>moderate</td><td>5(31.2%)</td><td>2(11.1%)</td><td>&#8212;</td></tr>
###xml 942 948 932 938 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">severe</td>
###xml 948 956 938 946 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">3(18.7%)</td>
###xml 956 957 946 947 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">0</td>
###xml 957 958 947 948 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#8212;</td>
###xml 942 958 932 948 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>severe</td><td>3(18.7%)</td><td>0</td><td>&#8212;</td></tr>
###xml 958 972 948 962 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Atopy/no atopy</td>
###xml 972 975 962 965 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">9/7</td>
###xml 975 979 965 969 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">8/10</td>
###xml 979 983 969 973 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">2/11</td>
###xml 958 983 948 973 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>Atopy/no atopy</td><td>9/7</td><td>8/10</td><td>2/11</td></tr>
###xml 983 995 973 985 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">PC20 (mg/ml)</td>
###xml 995 1006 985 994 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">8.89&#177;6.40</td>
###xml 1006 1016 994 1002 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">4.68&#177;2.9</td>
###xml 1016 1019 1002 1005 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&gt;16</td>
###xml 983 1019 973 1005 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>PC20 (mg/ml)</td><td>8.89&#177;6.40</td><td>4.68&#177;2.9</td><td>&gt;16</td></tr>
###xml 1019 1039 1005 1025 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">FEV1 (% pred. value)</td>
###xml 1039 1052 1025 1036 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">85.75&#177;19.40</td>
###xml 1052 1063 1036 1045 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">99.3&#177;17.4</td>
###xml 1063 1075 1045 1055 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">109.79&#177;9.1</td>
###xml 1019 1075 1005 1055 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>FEV1 (% pred. value)</td><td>85.75&#177;19.40</td><td>99.3&#177;17.4</td><td>109.79&#177;9.1</td></tr>
###xml 1075 1094 1055 1074 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">PEF (% pred. value)</td>
###xml 1094 1107 1074 1085 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">67.27&#177;18.20</td>
###xml 1107 1118 1085 1094 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">86.5&#177;23.1</td>
###xml 1118 1129 1094 1103 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">88.6&#177;12.4</td>
###xml 1075 1129 1055 1103 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>PEF (% pred. value)</td><td>67.27&#177;18.20</td><td>86.5&#177;23.1</td><td>88.6&#177;12.4</td></tr>
###xml 1129 1137 1103 1111 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">FEV1%FVC</td>
###xml 1137 1150 1111 1122 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">75.72&#177;13.57</td>
###xml 1150 1161 1122 1131 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">79.34&#177;8.8</td>
###xml 1161 1172 1131 1140 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">82.4&#177;10.0</td>
###xml 1129 1172 1103 1140 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>FEV1%FVC</td><td>75.72&#177;13.57</td><td>79.34&#177;8.8</td><td>82.4&#177;10.0</td></tr>
###xml 1172 1184 1140 1152 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">ICS doses:**</td>
###xml 1184 1184 1152 1152 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1184 1184 1152 1152 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1184 1184 1152 1152 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1172 1184 1140 1152 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>ICS doses:**</td><td/><td/><td/></tr>
###xml 1184 1209 1152 1173 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">small: 200&#8211;600 &#181;g/die</td>
###xml 1209 1214 1173 1178 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">16.6%</td>
###xml 1214 1215 1178 1179 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#8212;</td>
###xml 1215 1216 1179 1180 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#8212;</td>
###xml 1184 1216 1152 1180 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>small: 200&#8211;600 &#181;g/die</td><td>16.6%</td><td>&#8212;</td><td>&#8212;</td></tr>
###xml 1216 1245 1180 1205 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">moderate: 600&#8211;1000 &#181;g/die</td>
###xml 1245 1250 1205 1210 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">41.6%</td>
###xml 1250 1251 1210 1211 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#8212;</td>
###xml 1251 1252 1211 1212 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#8212;</td>
###xml 1216 1252 1180 1212 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>moderate: 600&#8211;1000 &#181;g/die</td><td>41.6%</td><td>&#8212;</td><td>&#8212;</td></tr>
###xml 1252 1277 1212 1231 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">large: &#8805;1000 &#181;g/die</td>
###xml 1277 1282 1231 1236 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">41.6%</td>
###xml 1282 1283 1236 1237 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#8212;</td>
###xml 1283 1284 1237 1238 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#8212;</td>
###xml 1252 1284 1212 1238 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>large: &#8805;1000 &#181;g/die</td><td>41.6%</td><td>&#8212;</td><td>&#8212;</td></tr>
###xml 1284 1307 1238 1261 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">ICS use length (years):</td>
###xml 1307 1307 1261 1261 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1307 1307 1261 1261 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1307 1307 1261 1261 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1284 1307 1238 1261 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>ICS use length (years):</td><td/><td/><td/></tr>
###xml 1307 1317 1261 1271 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">range/mean</td>
###xml 1317 1336 1271 1288 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1-12.5/(4.9&#177;3.58)</td>
###xml 1336 1337 1288 1289 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#8212;</td>
###xml 1337 1338 1289 1290 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#8212;</td>
###xml 1307 1338 1261 1290 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>range/mean</td><td>1-12.5/(4.9&#177;3.58)</td><td>&#8212;</td><td>&#8212;</td></tr>
###xml 1338 1401 1290 1353 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Smoking cigarettes history positive (%) (always &lt;10 pack-years)</td>
###xml 1401 1406 1353 1358 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">18.7%</td>
###xml 1406 1411 1358 1363 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">22.2%</td>
###xml 1411 1413 1363 1365 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">0%</td>
###xml 1338 1413 1290 1365 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>Smoking cigarettes history positive (%) (always &lt;10 pack-years)</td><td>18.7%</td><td>22.2%</td><td>0%</td></tr>
###xml 726 1413 726 1365 <tbody xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td/><td>LSA group n=16</td><td>RDA group n=18</td><td>Controls n=13</td></tr><tr><td>Age (years)*</td><td>49.10&#177;15.50</td><td>41.6&#177;13.5</td><td>46.92&#177;14.7</td></tr><tr><td>Sex: F/M</td><td>15/1</td><td>17/1</td><td>10/3</td></tr><tr><td>Asthma duration (years)</td><td>14.50&#177;12.70</td><td>1.7&#177;1.3</td><td>&#8212;</td></tr><tr><td>Asthma severity:</td><td/><td/><td/></tr><tr><td>mild</td><td>8(50%)</td><td>16(88.8%)</td><td>&#8212;</td></tr><tr><td>moderate</td><td>5(31.2%)</td><td>2(11.1%)</td><td>&#8212;</td></tr><tr><td>severe</td><td>3(18.7%)</td><td>0</td><td>&#8212;</td></tr><tr><td>Atopy/no atopy</td><td>9/7</td><td>8/10</td><td>2/11</td></tr><tr><td>PC20 (mg/ml)</td><td>8.89&#177;6.40</td><td>4.68&#177;2.9</td><td>&gt;16</td></tr><tr><td>FEV1 (% pred. value)</td><td>85.75&#177;19.40</td><td>99.3&#177;17.4</td><td>109.79&#177;9.1</td></tr><tr><td>PEF (% pred. value)</td><td>67.27&#177;18.20</td><td>86.5&#177;23.1</td><td>88.6&#177;12.4</td></tr><tr><td>FEV1%FVC</td><td>75.72&#177;13.57</td><td>79.34&#177;8.8</td><td>82.4&#177;10.0</td></tr><tr><td>ICS doses:**</td><td/><td/><td/></tr><tr><td>small: 200&#8211;600 &#181;g/die</td><td>16.6%</td><td>&#8212;</td><td>&#8212;</td></tr><tr><td>moderate: 600&#8211;1000 &#181;g/die</td><td>41.6%</td><td>&#8212;</td><td>&#8212;</td></tr><tr><td>large: &#8805;1000 &#181;g/die</td><td>41.6%</td><td>&#8212;</td><td>&#8212;</td></tr><tr><td>ICS use length (years):</td><td/><td/><td/></tr><tr><td>range/mean</td><td>1-12.5/(4.9&#177;3.58)</td><td>&#8212;</td><td>&#8212;</td></tr><tr><td>Smoking cigarettes history positive (%) (always &lt;10 pack-years)</td><td>18.7%</td><td>22.2%</td><td>0%</td></tr></tbody>
###xml 726 1413 726 1365 <table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><tbody><tr><td/><td>LSA group n=16</td><td>RDA group n=18</td><td>Controls n=13</td></tr><tr><td>Age (years)*</td><td>49.10&#177;15.50</td><td>41.6&#177;13.5</td><td>46.92&#177;14.7</td></tr><tr><td>Sex: F/M</td><td>15/1</td><td>17/1</td><td>10/3</td></tr><tr><td>Asthma duration (years)</td><td>14.50&#177;12.70</td><td>1.7&#177;1.3</td><td>&#8212;</td></tr><tr><td>Asthma severity:</td><td/><td/><td/></tr><tr><td>mild</td><td>8(50%)</td><td>16(88.8%)</td><td>&#8212;</td></tr><tr><td>moderate</td><td>5(31.2%)</td><td>2(11.1%)</td><td>&#8212;</td></tr><tr><td>severe</td><td>3(18.7%)</td><td>0</td><td>&#8212;</td></tr><tr><td>Atopy/no atopy</td><td>9/7</td><td>8/10</td><td>2/11</td></tr><tr><td>PC20 (mg/ml)</td><td>8.89&#177;6.40</td><td>4.68&#177;2.9</td><td>&gt;16</td></tr><tr><td>FEV1 (% pred. value)</td><td>85.75&#177;19.40</td><td>99.3&#177;17.4</td><td>109.79&#177;9.1</td></tr><tr><td>PEF (% pred. value)</td><td>67.27&#177;18.20</td><td>86.5&#177;23.1</td><td>88.6&#177;12.4</td></tr><tr><td>FEV1%FVC</td><td>75.72&#177;13.57</td><td>79.34&#177;8.8</td><td>82.4&#177;10.0</td></tr><tr><td>ICS doses:**</td><td/><td/><td/></tr><tr><td>small: 200&#8211;600 &#181;g/die</td><td>16.6%</td><td>&#8212;</td><td>&#8212;</td></tr><tr><td>moderate: 600&#8211;1000 &#181;g/die</td><td>41.6%</td><td>&#8212;</td><td>&#8212;</td></tr><tr><td>large: &#8805;1000 &#181;g/die</td><td>41.6%</td><td>&#8212;</td><td>&#8212;</td></tr><tr><td>ICS use length (years):</td><td/><td/><td/></tr><tr><td>range/mean</td><td>1-12.5/(4.9&#177;3.58)</td><td>&#8212;</td><td>&#8212;</td></tr><tr><td>Smoking cigarettes history positive (%) (always &lt;10 pack-years)</td><td>18.7%</td><td>22.2%</td><td>0%</td></tr></tbody></table>
###xml 1413 1548 1365 1500 <p xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" textid="16">ICS &#8212; inhaled corticosteroids, LSA &#8212; long-standing asthmatics treated with ICS, RDA &#8212; recently diagnosed asthmatics untreated with ICS.</p>
###xml 1548 1677 1500 1627 <p xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" textid="17">* Values are expressed as means &#177;SEMs, except for cases where showed differently, **ICS dose during last 3 months (budesonide).</p>
###xml 1413 1677 1365 1627 <table-wrap-foot xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="16">ICS &#8212; inhaled corticosteroids, LSA &#8212; long-standing asthmatics treated with ICS, RDA &#8212; recently diagnosed asthmatics untreated with ICS.</p><p textid="17">* Values are expressed as means &#177;SEMs, except for cases where showed differently, **ICS dose during last 3 months (budesonide).</p></table-wrap-foot>
###xml 695 1677 695 1627 <table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab1"><label>Table 1</label><caption><p textid="15">Subjects&#8217; characteristic</p></caption><table frame="hsides" rules="groups"><tbody><tr><td/><td>LSA group n=16</td><td>RDA group n=18</td><td>Controls n=13</td></tr><tr><td>Age (years)*</td><td>49.10&#177;15.50</td><td>41.6&#177;13.5</td><td>46.92&#177;14.7</td></tr><tr><td>Sex: F/M</td><td>15/1</td><td>17/1</td><td>10/3</td></tr><tr><td>Asthma duration (years)</td><td>14.50&#177;12.70</td><td>1.7&#177;1.3</td><td>&#8212;</td></tr><tr><td>Asthma severity:</td><td/><td/><td/></tr><tr><td>mild</td><td>8(50%)</td><td>16(88.8%)</td><td>&#8212;</td></tr><tr><td>moderate</td><td>5(31.2%)</td><td>2(11.1%)</td><td>&#8212;</td></tr><tr><td>severe</td><td>3(18.7%)</td><td>0</td><td>&#8212;</td></tr><tr><td>Atopy/no atopy</td><td>9/7</td><td>8/10</td><td>2/11</td></tr><tr><td>PC20 (mg/ml)</td><td>8.89&#177;6.40</td><td>4.68&#177;2.9</td><td>&gt;16</td></tr><tr><td>FEV1 (% pred. value)</td><td>85.75&#177;19.40</td><td>99.3&#177;17.4</td><td>109.79&#177;9.1</td></tr><tr><td>PEF (% pred. value)</td><td>67.27&#177;18.20</td><td>86.5&#177;23.1</td><td>88.6&#177;12.4</td></tr><tr><td>FEV1%FVC</td><td>75.72&#177;13.57</td><td>79.34&#177;8.8</td><td>82.4&#177;10.0</td></tr><tr><td>ICS doses:**</td><td/><td/><td/></tr><tr><td>small: 200&#8211;600 &#181;g/die</td><td>16.6%</td><td>&#8212;</td><td>&#8212;</td></tr><tr><td>moderate: 600&#8211;1000 &#181;g/die</td><td>41.6%</td><td>&#8212;</td><td>&#8212;</td></tr><tr><td>large: &#8805;1000 &#181;g/die</td><td>41.6%</td><td>&#8212;</td><td>&#8212;</td></tr><tr><td>ICS use length (years):</td><td/><td/><td/></tr><tr><td>range/mean</td><td>1-12.5/(4.9&#177;3.58)</td><td>&#8212;</td><td>&#8212;</td></tr><tr><td>Smoking cigarettes history positive (%) (always &lt;10 pack-years)</td><td>18.7%</td><td>22.2%</td><td>0%</td></tr></tbody></table><table-wrap-foot><p textid="16">ICS &#8212; inhaled corticosteroids, LSA &#8212; long-standing asthmatics treated with ICS, RDA &#8212; recently diagnosed asthmatics untreated with ICS.</p><p textid="17">* Values are expressed as means &#177;SEMs, except for cases where showed differently, **ICS dose during last 3 months (budesonide).</p></table-wrap-foot></table-wrap>
###xml 12 20 <span type="species:ncbi:9606">patients</span>
Thirty-four patients with asthma fulfilling the criteria of the Global Initiative for Asthma of the NHLBI/WHO were recruited (Table 1). They were further divided into two groups: the long-standing asthma group (LSA), with 16 subjects with asthma duration of at least 4 years treated with inhaled corticosteroids (ICS), and the recently diagnosed asthma group (RDA), with 18 subjects with asthma duration of less than 4 years untreated with ICS. The control group consisted of 13 subjects with no history of asthma (Table 1). The study was approved by the Ethics Committee of the Wroclaw Medical University and written informed consent was obtained from all subjects before entry into the study. Table 1Subjects' characteristicLSA group n=16RDA group n=18Controls n=13Age (years)*49.10+/-15.5041.6+/-13.546.92+/-14.7Sex: F/M15/117/110/3Asthma duration (years)14.50+/-12.701.7+/-1.3-Asthma severity:mild8(50%)16(88.8%)-moderate5(31.2%)2(11.1%)-severe3(18.7%)0-Atopy/no atopy9/78/102/11PC20 (mg/ml)8.89+/-6.404.68+/-2.9>16FEV1 (% pred. value)85.75+/-19.4099.3+/-17.4109.79+/-9.1PEF (% pred. value)67.27+/-18.2086.5+/-23.188.6+/-12.4FEV1%FVC75.72+/-13.5779.34+/-8.882.4+/-10.0ICS doses:**small: 200-600 microg/die16.6%--moderate: 600-1000 microg/die41.6%--large: >/=1000 microg/die41.6%--ICS use length (years):range/mean1-12.5/(4.9+/-3.58)--Smoking cigarettes history positive (%) (always <10 pack-years)18.7%22.2%0%ICS - inhaled corticosteroids, LSA - long-standing asthmatics treated with ICS, RDA - recently diagnosed asthmatics untreated with ICS.* Values are expressed as means +/-SEMs, except for cases where showed differently, **ICS dose during last 3 months (budesonide).
###end p 14
###begin p 15
Subjects' characteristic
###end p 15
###begin p 16
ICS - inhaled corticosteroids, LSA - long-standing asthmatics treated with ICS, RDA - recently diagnosed asthmatics untreated with ICS.
###end p 16
###begin p 17
* Values are expressed as means +/-SEMs, except for cases where showed differently, **ICS dose during last 3 months (budesonide).
###end p 17
###begin title 18
Lung function and challenge procedure
###end title 18
###begin p 19
###xml 59 60 59 60 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 65 66 65 66 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 418 420 418 420 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR20">20</xref>
Pulmonary function tests included three measurements of FEV1, FEV1/FVC, and PEF with a flow-screen spirometer (Jaeger GMBH & CoKH, Germany). The reversibility of airway obstruction was investigated in response to inhaled salbutamol. Histamine challenge tests were carried out using computer software with a special protocol developed at the Department of Internal Medicine and Allergology, Wroclaw Medical University [20], with a De Vilbiss 646 nebulizer.
###end p 19
###begin title 20
Fiberoptic bronchoscopy
###end title 20
###begin p 21
###xml 56 57 56 57 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">7</xref>
###xml 330 332 330 332 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR28">28</xref>
Bronchoscopy was performed according to BTS guidelines [7]. The subjects were premedicated with 0.5 mg atropine s.c. and 25 mg pethidine i.v. During bronchoscopy, visual assessment of airway inflammation was done and the macroscopic bronchitis index was derived (0-3 scale) depending on the presence of abnormal mucosal features [28]. Two to three biopsies were collected from the subcarinae of the right upper lobe using a Pentax FB18X bronchoscope, fixed in formalin solution, and embedded in paraffin.
###end p 21
###begin title 22
Tissue processing and immunohistochemistry
###end title 22
###begin p 23
###xml 424 426 424 426 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR28">28</xref>
Biopsy specimens coded prior to analysis were studied histologically and immunohistochemically. A histopathologist assessed the features of mucosal inflammation and on that basis the microscopic inflammation index was introduced. This index was used to differentiate the degree of mucosal inflammation in the biopsies and to compare it with the macroscopic inflammation index (bronchitis index according to Thompson et al. [28]). The microscopic inflammation index was evaluated semiquantitatively by the histopathologist on the basis of the presence of inflammatory cells in the mucosa (1 - small inflammation, 2 - moderate, 3 - large degree of inflammation).
###end p 23
###begin p 24
###xml 104 106 104 106 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR26">26</xref>
###xml 127 128 124 125 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 216 217 210 211 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 749 750 740 741 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 197 202 <span type="species:ncbi:10090">mouse</span>
###xml 300 305 <span type="species:ncbi:10090">mouse</span>
For immunohistochemistry, the sections were stained using the streptavidin-biotin-peroxidase technique [26]. To assess TGF-beta1 and collagen type III expression the sections were incubated with a mouse anti-TGF-beta1 monoclonal antibody (dilution 1:20, Novo Castra Laboratories, England) and with a mouse anti-collagen III monoclonal antibody (dilution 1:100, Medicorp, Canada), respectively. All the sections were then incubated with biotinylated antibody (LSAB Kit, Dako, USA) and with a streptavidin-biotin-peroxidase complex (LSAB Kit, Dako, USA). They were subsequently developed in 3,3-diaminobenzidine (DAB, Liquid K, Dako, US). Skin samples were used as a positive control for anti-collagen III antibodies and the placenta for anti-TGF-beta1 antibodies. Sections in which the primary antibodies were omitted served as a negative control.
###end p 24
###begin p 25
###xml 207 208 204 205 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
Immunohistochemical staining was assessed with an Olympus BH-2 light microscope at a magnification of 200x in a semiquantitative analysis with the visual scale. Two parameters were used to determine TGF-beta1 expression and collagen type III deposition within the epithelium and subepithelial area in the airways. The first was the extent of the tissue area which was stained immunohistochemically and is presented as the percentage of the total tissue area and the second was the intensity of the immunohistochemical staining. Both were assessed semiquantitatively. The staining intensity was assessed on a scale of 0 to 3 (0 - no expression, 1 - poor expression, 2 - moderate expression, 3 - strong expression). Both these parameters correlated positively with each other.
###end p 25
###begin p 26
###xml 238 245 <span type="species:ncbi:9606">patient</span>
Total basement membrane (TBM) thickness (the "true" basement membrane and RBM together) was assessed on sections stained with toluidine blue using a Multiscan 08.98 computer-assisted image analysis system, making 10 measurements for each patient along the basement membrane from the base of the epithelium to the outer limit of the RBM.
###end p 26
###begin title 27
Statistical analysis
###end title 27
###begin p 28
###xml 227 228 222 223 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 312 313 307 308 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
MS EXCEL software was used for the statistical analysis. Results are given as the mean +/-SD. Of the analyzed features, BHR, TBM, and collagen III deposition had normal distributions, while epithelial and subepithelial TGF-beta1 expressions were right-skewed, so a logarithmic transformation was used. Student's t-test was applied to compare two groups and the chi-squared test to assess the frequency in the groups. Additionally, Fisher's exact test as well as Scheffe's and Levene's tests were performed.
###end p 28
###begin title 29
Results
###end title 29
###begin p 30
###xml 146 147 146 147 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 237 238 237 238 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 274 275 274 275 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 278 284 278 284 <label xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Fig. 1</label>
###xml 284 326 284 326 <p xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" textid="31">Scatterplot: astma duration (ln) vs. FEV1.</p>
###xml 284 326 284 326 <caption xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="31">Scatterplot: astma duration (ln) vs. FEV1.</p></caption>
###xml 326 326 326 326 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="5_2008_Article_44_Fig1" id="MO1"/>
###xml 278 326 278 326 <fig xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig1"><label>Fig. 1</label><caption><p textid="31">Scatterplot: astma duration (ln) vs. FEV1.</p></caption><graphic xlink:href="5_2008_Article_44_Fig1" id="MO1"/></fig>
###xml 175 183 <span type="species:ncbi:9606">Patients</span>
The groups did not differ with regard to age or sex. Lung function parameters were significantly lower in the LSA group than in the RDA group (FEV1%: p=0.039, FVC%: p=0.012). Patients with asthma showed a negative correlation between FEV1 and asthma duration (p=0.004; Fig. 1). Fig. 1Scatterplot: astma duration (ln) vs. FEV1.
###end p 30
###begin p 31
Scatterplot: astma duration (ln) vs. FEV1.
###end p 31
###begin p 32
###xml 149 150 147 148 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 262 263 260 261 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 363 364 358 359 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 559 565 554 560 <label xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Fig. 2</label>
###xml 565 610 560 605 <p xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" textid="33">Scatterplot: ICS-treatment duration vs. PC20.</p>
###xml 565 610 560 605 <caption xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="33">Scatterplot: ICS-treatment duration vs. PC20.</p></caption>
###xml 610 610 605 605 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="5_2008_Article_44_Fig2" id="MO2"/>
###xml 559 610 554 605 <fig xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig2"><label>Fig. 2</label><caption><p textid="33">Scatterplot: ICS-treatment duration vs. PC20.</p></caption><graphic xlink:href="5_2008_Article_44_Fig2" id="MO2"/></fig>
The mean PC20 value in all asthmatics was 6.58+/-5.24 mg/ml. Mean PC20 was significantly lower in the RDA group than in the LSA group (p=0.02; Table 1). A significant positive correlation between PC20 values and ICS treatment duration was observed (p<0.05; Fig. 2). No correlations were found between PC20 values and spirometric indices, asthma duration, TGF-beta1 expression, TBM thickness, or collagen type III mucosal expression. PC20 values were not significantly differentiated with regard to microscopic or macroscopic features of mucosal inflammation. Fig. 2Scatterplot: ICS-treatment duration vs. PC20.
###end p 32
###begin p 33
Scatterplot: ICS-treatment duration vs. PC20.
###end p 33
###begin p 34
###xml 130 131 118 119 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
###xml 257 258 245 246 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
###xml 361 362 349 350 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 440 441 428 429 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 444 451 432 439 <label xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Table 2</label>
###xml 451 525 439 513 <p xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" textid="35">Total basement membrane thickness and collagen III deposition measurements</p>
###xml 451 525 439 513 <caption xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="35">Total basement membrane thickness and collagen III deposition measurements</p></caption>
###xml 525 525 513 513 <th xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="2"/>
###xml 525 537 513 521 <th xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="2">TBM (&#181;M)</th>
###xml 537 563 521 547 <th xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" colspan="2">Subepithelial collagen III</th>
###xml 525 563 513 547 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><th rowspan="2"/><th rowspan="2">TBM (&#181;M)</th><th colspan="2">Subepithelial collagen III</th></tr>
###xml 563 577 547 561 <th xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">expression (%)</th>
###xml 577 586 561 570 <th xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">intensity</th>
###xml 563 586 547 570 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><th>expression (%)</th><th>intensity</th></tr>
###xml 525 586 513 570 <thead xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th rowspan="2"/><th rowspan="2">TBM (&#181;M)</th><th colspan="2">Subepithelial collagen III</th></tr><tr><th>expression (%)</th><th>intensity</th></tr></thead>
###xml 586 596 570 580 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">LSA (ICS+)</td>
###xml 596 608 580 590 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">10.52&#177;3.11</td>
###xml 608 619 590 599 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">59.0&#177;42.6</td>
###xml 619 630 599 608 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1.70&#177;1.13</td>
###xml 586 630 570 608 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>LSA (ICS+)</td><td>10.52&#177;3.11</td><td>59.0&#177;42.6</td><td>1.70&#177;1.13</td></tr>
###xml 630 633 608 611 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">RDA</td>
###xml 633 644 611 620 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">6.85&#177;1.89</td>
###xml 644 656 620 630 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">65.29&#177;34.2</td>
###xml 656 667 630 639 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1.76&#177;0.93</td>
###xml 630 667 608 639 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>RDA</td><td>6.85&#177;1.89</td><td>65.29&#177;34.2</td><td>1.76&#177;0.93</td></tr>
###xml 667 675 639 647 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Controls</td>
###xml 675 686 647 656 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">3.25&#177;0.96</td>
###xml 686 698 656 666 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">54.16&#177;39.8</td>
###xml 698 709 666 675 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1.66&#177;0.88</td>
###xml 667 709 639 675 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>Controls</td><td>3.25&#177;0.96</td><td>54.16&#177;39.8</td><td>1.66&#177;0.88</td></tr>
###xml 709 717 675 683 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p values</td>
###xml 717 724 683 690 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&lt;0.001*</td>
###xml 724 728 690 694 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">0.74</td>
###xml 728 731 694 697 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">0.8</td>
###xml 709 731 675 697 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>p values</td><td>&lt;0.001*</td><td>0.74</td><td>0.8</td></tr>
###xml 586 731 570 697 <tbody xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td>LSA (ICS+)</td><td>10.52&#177;3.11</td><td>59.0&#177;42.6</td><td>1.70&#177;1.13</td></tr><tr><td>RDA</td><td>6.85&#177;1.89</td><td>65.29&#177;34.2</td><td>1.76&#177;0.93</td></tr><tr><td>Controls</td><td>3.25&#177;0.96</td><td>54.16&#177;39.8</td><td>1.66&#177;0.88</td></tr><tr><td>p values</td><td>&lt;0.001*</td><td>0.74</td><td>0.8</td></tr></tbody>
###xml 525 731 513 697 <table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th rowspan="2"/><th rowspan="2">TBM (&#181;M)</th><th colspan="2">Subepithelial collagen III</th></tr><tr><th>expression (%)</th><th>intensity</th></tr></thead><tbody><tr><td>LSA (ICS+)</td><td>10.52&#177;3.11</td><td>59.0&#177;42.6</td><td>1.70&#177;1.13</td></tr><tr><td>RDA</td><td>6.85&#177;1.89</td><td>65.29&#177;34.2</td><td>1.76&#177;0.93</td></tr><tr><td>Controls</td><td>3.25&#177;0.96</td><td>54.16&#177;39.8</td><td>1.66&#177;0.88</td></tr><tr><td>p values</td><td>&lt;0.001*</td><td>0.74</td><td>0.8</td></tr></tbody></table>
###xml 731 892 697 856 <p xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" textid="36">All values are expressed as means &#177;SD. LSA (ICS+) &#8212; longstanding asthma group treated with ICS, RDA &#8212; recently diagnosed asthma, TBM &#8212; total basement membrane.</p>
###xml 892 920 856 884 <p xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" textid="37">* Statistically significant.</p>
###xml 731 920 697 884 <table-wrap-foot xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="36">All values are expressed as means &#177;SD. LSA (ICS+) &#8212; longstanding asthma group treated with ICS, RDA &#8212; recently diagnosed asthma, TBM &#8212; total basement membrane.</p><p textid="37">* Statistically significant.</p></table-wrap-foot>
###xml 444 920 432 884 <table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab2"><label>Table 2</label><caption><p textid="35">Total basement membrane thickness and collagen III deposition measurements</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2"/><th rowspan="2">TBM (&#181;M)</th><th colspan="2">Subepithelial collagen III</th></tr><tr><th>expression (%)</th><th>intensity</th></tr></thead><tbody><tr><td>LSA (ICS+)</td><td>10.52&#177;3.11</td><td>59.0&#177;42.6</td><td>1.70&#177;1.13</td></tr><tr><td>RDA</td><td>6.85&#177;1.89</td><td>65.29&#177;34.2</td><td>1.76&#177;0.93</td></tr><tr><td>Controls</td><td>3.25&#177;0.96</td><td>54.16&#177;39.8</td><td>1.66&#177;0.88</td></tr><tr><td>p values</td><td>&lt;0.001*</td><td>0.74</td><td>0.8</td></tr></tbody></table><table-wrap-foot><p textid="36">All values are expressed as means &#177;SD. LSA (ICS+) &#8212; longstanding asthma group treated with ICS, RDA &#8212; recently diagnosed asthma, TBM &#8212; total basement membrane.</p><p textid="37">* Statistically significant.</p></table-wrap-foot></table-wrap>
###xml 920 926 884 890 <label xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Fig. 3</label>
###xml 926 972 890 936 <p xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" textid="38">Scatterplot: astma duration vs. TBM thickness.</p>
###xml 926 972 890 936 <caption xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="38">Scatterplot: astma duration vs. TBM thickness.</p></caption>
###xml 972 972 936 936 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="5_2008_Article_44_Fig3" id="MO3"/>
###xml 920 972 884 936 <fig xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig3"><label>Fig. 3</label><caption><p textid="38">Scatterplot: astma duration vs. TBM thickness.</p></caption><graphic xlink:href="5_2008_Article_44_Fig3" id="MO3"/></fig>
###xml 4 12 <span type="species:ncbi:9606">patients</span>
The patients with asthma had thicker TBM (mean: 8.56+/-3.11 microm) than the control subjects (3.25+/-0.96 microm; p<0.001; Table 2). Moreover, in spite of steroid treatment, there was significantly thicker TBM in the LSA group than in the RDA group (Table 2). Significant positive correlation was found between TBM thickness and asthma duration (p=0.004; Fig. 3). There was no clear correlation between TBM thickness and lung function (FEV1). Table 2Total basement membrane thickness and collagen III deposition measurementsTBM (microM)Subepithelial collagen IIIexpression (%)intensityLSA (ICS+)10.52+/-3.1159.0+/-42.61.70+/-1.13RDA6.85+/-1.8965.29+/-34.21.76+/-0.93Controls3.25+/-0.9654.16+/-39.81.66+/-0.88p values<0.001*0.740.8All values are expressed as means +/-SD. LSA (ICS+) - longstanding asthma group treated with ICS, RDA - recently diagnosed asthma, TBM - total basement membrane.* Statistically significant.Fig. 3Scatterplot: astma duration vs. TBM thickness.
###end p 34
###begin p 35
Total basement membrane thickness and collagen III deposition measurements
###end p 35
###begin p 36
All values are expressed as means +/-SD. LSA (ICS+) - longstanding asthma group treated with ICS, RDA - recently diagnosed asthma, TBM - total basement membrane.
###end p 36
###begin p 37
* Statistically significant.
###end p 37
###begin p 38
Scatterplot: astma duration vs. TBM thickness.
###end p 38
###begin p 39
###xml 103 104 103 104 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
The expression of collagen type III in the subepithelial area was similar in the studied groups (Table 2). No correlations were found between collagen III deposition and lung function. There were also no significant correlations observed between TBM thickness and collagen III deposition.
###end p 39
###begin p 40
###xml 8 9 5 6 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 145 146 142 143 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab3" ref-type="table">3</xref>
###xml 277 278 271 272 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 343 344 337 338 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig4" ref-type="fig">4</xref>
###xml 378 379 372 373 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig5" ref-type="fig">5</xref>
###xml 448 449 439 440 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 498 499 489 490 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig6" ref-type="fig">6</xref>
###xml 502 508 493 499 <label xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Fig. 4</label>
###xml 529 530 517 518 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 508 572 499 560 <p xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" textid="41">Scatterplot: TGF-&#946;<sub>1</sub> epithelial vs. collagen III in LSA group.</p>
###xml 508 572 499 560 <caption xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="41">Scatterplot: TGF-&#946;<sub>1</sub> epithelial vs. collagen III in LSA group.</p></caption>
###xml 572 572 560 560 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="5_2008_Article_44_Fig4" id="MO4"/>
###xml 502 572 493 560 <fig xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig4"><label>Fig. 4</label><caption><p textid="41">Scatterplot: TGF-&#946;<sub>1</sub> epithelial vs. collagen III in LSA group.</p></caption><graphic xlink:href="5_2008_Article_44_Fig4" id="MO4"/></fig>
###xml 572 578 560 566 <label xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Fig. 5</label>
###xml 599 600 584 585 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 578 633 566 618 <p xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" textid="42">Scatterplot: TGF-&#946;<sub>1</sub> epithelial vs. TBM in LSA group.</p>
###xml 578 633 566 618 <caption xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="42">Scatterplot: TGF-&#946;<sub>1</sub> epithelial vs. TBM in LSA group.</p></caption>
###xml 633 633 618 618 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="5_2008_Article_44_Fig5" id="MO5"/>
###xml 572 633 560 618 <fig xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig5"><label>Fig. 5</label><caption><p textid="42">Scatterplot: TGF-&#946;<sub>1</sub> epithelial vs. TBM in LSA group.</p></caption><graphic xlink:href="5_2008_Article_44_Fig5" id="MO5"/></fig>
###xml 633 633 618 618 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="5_2008_Article_44_Fig6" id="MO6"/>
###xml 633 633 618 618 <fig xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig6"><graphic xlink:href="5_2008_Article_44_Fig6" id="MO6"/></fig>
###xml 633 640 618 625 <label xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Table 3</label>
###xml 648 649 630 631 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 640 675 625 657 <p xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" textid="43">TGF-&#946;<sub>1</sub> expression in the airways</p>
###xml 640 675 625 657 <caption xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="43">TGF-&#946;<sub>1</sub> expression in the airways</p></caption>
###xml 675 675 657 657 <th xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 675 689 657 671 <th xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">All asthmatics</th>
###xml 689 699 671 681 <th xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">LSA (ICS+)</th>
###xml 699 702 681 684 <th xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">RDA</th>
###xml 702 710 684 692 <th xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Controls</th>
###xml 675 710 657 692 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><th/><th>All asthmatics</th><th>LSA (ICS+)</th><th>RDA</th><th>Controls</th></tr>
###xml 675 710 657 692 <thead xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th/><th>All asthmatics</th><th>LSA (ICS+)</th><th>RDA</th><th>Controls</th></tr></thead>
###xml 710 716 692 698 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Number</td>
###xml 716 718 698 700 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">34</td>
###xml 718 720 700 702 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">16</td>
###xml 720 722 702 704 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">18</td>
###xml 722 724 704 706 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">11</td>
###xml 710 724 692 706 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>Number</td><td>34</td><td>16</td><td>18</td><td>11</td></tr>
###xml 732 733 711 712 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 724 759 706 738 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">TGF-&#946;<sub>1</sub> epithelial expression (%)</td>
###xml 759 773 738 750 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">10.58 &#177; 24.2</td>
###xml 773 787 750 762 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">9.06 &#177; 24.09</td>
###xml 787 802 762 775 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">11.94 &#177; 24.91</td>
###xml 802 817 775 788 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">25.45 &#177; 36.70</td>
###xml 724 817 706 788 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>TGF-&#946;<sub>1</sub> epithelial expression (%)</td><td>10.58 &#177; 24.2</td><td>9.06 &#177; 24.09</td><td>11.94 &#177; 24.91</td><td>25.45 &#177; 36.70</td></tr>
###xml 825 826 793 794 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 817 855 788 823 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">TGF-&#946;<sub>1</sub> subepithelial expression (%)</td>
###xml 855 870 823 836 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">12.20 &#177; 24.03</td>
###xml 870 884 836 848 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">6.56 &#177; 10.11</td>
###xml 884 899 848 861 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">17.22 &#177; 31.21</td>
###xml 899 914 861 874 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">16.80 &#177; 27.40</td>
###xml 817 914 788 874 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>TGF-&#946;<sub>1</sub> subepithelial expression (%)</td><td>12.20 &#177; 24.03</td><td>6.56 &#177; 10.11</td><td>17.22 &#177; 31.21</td><td>16.80 &#177; 27.40</td></tr>
###xml 922 923 879 880 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 914 942 874 899 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">TGF-&#946;<sub>1</sub> mucosal intensity*</td>
###xml 942 955 899 910 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">0.83 &#177; 0.89</td>
###xml 955 968 910 921 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">0.81 &#177; 0.91</td>
###xml 968 981 921 932 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">0.86 &#177; 0.90</td>
###xml 981 994 932 943 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">0.81 &#177; 0.91</td>
###xml 914 994 874 943 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>TGF-&#946;<sub>1</sub> mucosal intensity*</td><td>0.83 &#177; 0.89</td><td>0.81 &#177; 0.91</td><td>0.86 &#177; 0.90</td><td>0.81 &#177; 0.91</td></tr>
###xml 710 994 692 943 <tbody xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td>Number</td><td>34</td><td>16</td><td>18</td><td>11</td></tr><tr><td>TGF-&#946;<sub>1</sub> epithelial expression (%)</td><td>10.58 &#177; 24.2</td><td>9.06 &#177; 24.09</td><td>11.94 &#177; 24.91</td><td>25.45 &#177; 36.70</td></tr><tr><td>TGF-&#946;<sub>1</sub> subepithelial expression (%)</td><td>12.20 &#177; 24.03</td><td>6.56 &#177; 10.11</td><td>17.22 &#177; 31.21</td><td>16.80 &#177; 27.40</td></tr><tr><td>TGF-&#946;<sub>1</sub> mucosal intensity*</td><td>0.83 &#177; 0.89</td><td>0.81 &#177; 0.91</td><td>0.86 &#177; 0.90</td><td>0.81 &#177; 0.91</td></tr></tbody>
###xml 675 994 657 943 <table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th/><th>All asthmatics</th><th>LSA (ICS+)</th><th>RDA</th><th>Controls</th></tr></thead><tbody><tr><td>Number</td><td>34</td><td>16</td><td>18</td><td>11</td></tr><tr><td>TGF-&#946;<sub>1</sub> epithelial expression (%)</td><td>10.58 &#177; 24.2</td><td>9.06 &#177; 24.09</td><td>11.94 &#177; 24.91</td><td>25.45 &#177; 36.70</td></tr><tr><td>TGF-&#946;<sub>1</sub> subepithelial expression (%)</td><td>12.20 &#177; 24.03</td><td>6.56 &#177; 10.11</td><td>17.22 &#177; 31.21</td><td>16.80 &#177; 27.40</td></tr><tr><td>TGF-&#946;<sub>1</sub> mucosal intensity*</td><td>0.83 &#177; 0.89</td><td>0.81 &#177; 0.91</td><td>0.86 &#177; 0.90</td><td>0.81 &#177; 0.91</td></tr></tbody></table>
###xml 994 1108 943 1055 <p xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" textid="44">All values are expressed as means &#177;SD; LSA(ICS+) &#8212; long -standing asthma group, RDA &#8212; recently diagnosed asthma.</p>
###xml 1108 1183 1055 1130 <p xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" textid="45">Mucosal intensity &#8212; analysis of epithelial and subepithelial area together.</p>
###xml 1183 1237 1130 1184 <p xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" textid="46">All differents not statistically significant (p&gt;0.05).</p>
###xml 994 1237 943 1184 <table-wrap-foot xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="44">All values are expressed as means &#177;SD; LSA(ICS+) &#8212; long -standing asthma group, RDA &#8212; recently diagnosed asthma.</p><p textid="45">Mucosal intensity &#8212; analysis of epithelial and subepithelial area together.</p><p textid="46">All differents not statistically significant (p&gt;0.05).</p></table-wrap-foot>
###xml 633 1237 618 1184 <table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab3"><label>Table 3</label><caption><p textid="43">TGF-&#946;<sub>1</sub> expression in the airways</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>All asthmatics</th><th>LSA (ICS+)</th><th>RDA</th><th>Controls</th></tr></thead><tbody><tr><td>Number</td><td>34</td><td>16</td><td>18</td><td>11</td></tr><tr><td>TGF-&#946;<sub>1</sub> epithelial expression (%)</td><td>10.58 &#177; 24.2</td><td>9.06 &#177; 24.09</td><td>11.94 &#177; 24.91</td><td>25.45 &#177; 36.70</td></tr><tr><td>TGF-&#946;<sub>1</sub> subepithelial expression (%)</td><td>12.20 &#177; 24.03</td><td>6.56 &#177; 10.11</td><td>17.22 &#177; 31.21</td><td>16.80 &#177; 27.40</td></tr><tr><td>TGF-&#946;<sub>1</sub> mucosal intensity*</td><td>0.83 &#177; 0.89</td><td>0.81 &#177; 0.91</td><td>0.86 &#177; 0.90</td><td>0.81 &#177; 0.91</td></tr></tbody></table><table-wrap-foot><p textid="44">All values are expressed as means &#177;SD; LSA(ICS+) &#8212; long -standing asthma group, RDA &#8212; recently diagnosed asthma.</p><p textid="45">Mucosal intensity &#8212; analysis of epithelial and subepithelial area together.</p><p textid="46">All differents not statistically significant (p&gt;0.05).</p></table-wrap-foot></table-wrap>
TGF-beta1 was rarely expressed in the epithelial cells of asthmatic airways, particularly in the LSA group compared with control subjects (Table 3), although these differences were not statistically significant. In the LSA group, negative correlation was found between TGF-beta1 epithelial expression and collagen III deposition (p=0.03; Fig. 4) and TBM thickness (p=0.05; Fig. 5). In the RDA group, positive correlation between epithelial TGF-beta1 expression and lung function was observed (Fig. 6). Fig. 4Scatterplot: TGF-beta1 epithelial vs. collagen III in LSA group.Fig. 5Scatterplot: TGF-beta1 epithelial vs. TBM in LSA group.Table 3TGF-beta1 expression in the airwaysAll asthmaticsLSA (ICS+)RDAControlsNumber34161811TGF-beta1 epithelial expression (%)10.58 +/- 24.29.06 +/- 24.0911.94 +/- 24.9125.45 +/- 36.70TGF-beta1 subepithelial expression (%)12.20 +/- 24.036.56 +/- 10.1117.22 +/- 31.2116.80 +/- 27.40TGF-beta1 mucosal intensity*0.83 +/- 0.890.81 +/- 0.910.86 +/- 0.900.81 +/- 0.91All values are expressed as means +/-SD; LSA(ICS+) - long -standing asthma group, RDA - recently diagnosed asthma.Mucosal intensity - analysis of epithelial and subepithelial area together.All differents not statistically significant (p>0.05).
###end p 40
###begin p 41
###xml 21 22 18 19 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
Scatterplot: TGF-beta1 epithelial vs. collagen III in LSA group.
###end p 41
###begin p 42
###xml 21 22 18 19 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
Scatterplot: TGF-beta1 epithelial vs. TBM in LSA group.
###end p 42
###begin p 43
###xml 8 9 5 6 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
TGF-beta1 expression in the airways
###end p 43
###begin p 44
All values are expressed as means +/-SD; LSA(ICS+) - long -standing asthma group, RDA - recently diagnosed asthma.
###end p 44
###begin p 45
Mucosal intensity - analysis of epithelial and subepithelial area together.
###end p 45
###begin p 46
All differents not statistically significant (p>0.05).
###end p 46
###begin p 47
###xml 122 123 122 123 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig7" ref-type="fig">7</xref>
###xml 124 126 124 126 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig11" ref-type="fig">11</xref>
###xml 128 134 128 134 <label xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Fig. 7</label>
###xml 134 362 134 362 <p xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" textid="48">Photomicrograph of a bronchial biopsy from a patient with long-standing atopic asthma (staining with toluidine blue) showing thickening of the basement membrane and deposition of extracellular matrix below the basement membrane.</p>
###xml 134 362 134 362 <caption xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="48">Photomicrograph of a bronchial biopsy from a patient with long-standing atopic asthma (staining with toluidine blue) showing thickening of the basement membrane and deposition of extracellular matrix below the basement membrane.</p></caption>
###xml 362 362 362 362 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="5_2008_Article_44_Fig7" id="MO7"/>
###xml 128 362 128 362 <fig xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig7"><label>Fig. 7</label><caption><p textid="48">Photomicrograph of a bronchial biopsy from a patient with long-standing atopic asthma (staining with toluidine blue) showing thickening of the basement membrane and deposition of extracellular matrix below the basement membrane.</p></caption><graphic xlink:href="5_2008_Article_44_Fig7" id="MO7"/></fig>
###xml 362 368 362 368 <label xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Fig. 8</label>
###xml 368 560 368 560 <p xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" textid="49">Photomicrograph of a bronchial biopsy from a healthy subject (staining with toluidine blue) showing epithelium, basement membrane, and a small amount of the subepithelial extracellular matrix.</p>
###xml 368 560 368 560 <caption xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="49">Photomicrograph of a bronchial biopsy from a healthy subject (staining with toluidine blue) showing epithelium, basement membrane, and a small amount of the subepithelial extracellular matrix.</p></caption>
###xml 560 560 560 560 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="5_2008_Article_44_Fig8" id="MO8"/>
###xml 362 560 362 560 <fig xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig8"><label>Fig. 8</label><caption><p textid="49">Photomicrograph of a bronchial biopsy from a healthy subject (staining with toluidine blue) showing epithelium, basement membrane, and a small amount of the subepithelial extracellular matrix.</p></caption><graphic xlink:href="5_2008_Article_44_Fig8" id="MO8"/></fig>
###xml 560 566 560 566 <label xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Fig. 9</label>
###xml 566 754 566 754 <p xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" textid="50">Photomicrograph of a bronchial biopsy from a patient with long-standing atopic asthma showing immunohistochemical staining with antibodies to collagen type III (brown collagen III fibers).</p>
###xml 566 754 566 754 <caption xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="50">Photomicrograph of a bronchial biopsy from a patient with long-standing atopic asthma showing immunohistochemical staining with antibodies to collagen type III (brown collagen III fibers).</p></caption>
###xml 754 754 754 754 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="5_2008_Article_44_Fig9" id="MO9"/>
###xml 560 754 560 754 <fig xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig9"><label>Fig. 9</label><caption><p textid="50">Photomicrograph of a bronchial biopsy from a patient with long-standing atopic asthma showing immunohistochemical staining with antibodies to collagen type III (brown collagen III fibers).</p></caption><graphic xlink:href="5_2008_Article_44_Fig9" id="MO9"/></fig>
###xml 754 761 754 761 <label xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Fig. 10</label>
###xml 761 947 761 947 <p xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" textid="51">Photomicrograph of a bronchial biopsy from a patient with recently diagnosed asthma showing immunohistochemical staining with antibodies to collagen type III (brown collagen III fibers).</p>
###xml 761 947 761 947 <caption xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="51">Photomicrograph of a bronchial biopsy from a patient with recently diagnosed asthma showing immunohistochemical staining with antibodies to collagen type III (brown collagen III fibers).</p></caption>
###xml 947 947 947 947 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="5_2008_Article_44_Fig10" id="MO10"/>
###xml 754 947 754 947 <fig xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig10"><label>Fig. 10</label><caption><p textid="51">Photomicrograph of a bronchial biopsy from a patient with recently diagnosed asthma showing immunohistochemical staining with antibodies to collagen type III (brown collagen III fibers).</p></caption><graphic xlink:href="5_2008_Article_44_Fig10" id="MO10"/></fig>
###xml 947 954 947 954 <label xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Fig. 11</label>
###xml 954 1119 954 1119 <p xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" textid="52">Photomicrographs of a bronchial biopsy from a healthy subjectc showing immunohistochemical staining with antibodies to collagen type III (brown collagen III fibers).</p>
###xml 954 1119 954 1119 <caption xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="52">Photomicrographs of a bronchial biopsy from a healthy subjectc showing immunohistochemical staining with antibodies to collagen type III (brown collagen III fibers).</p></caption>
###xml 1119 1119 1119 1119 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="5_2008_Article_44_Fig11" id="MO11"/>
###xml 947 1119 947 1119 <fig xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig11"><label>Fig. 11</label><caption><p textid="52">Photomicrographs of a bronchial biopsy from a healthy subjectc showing immunohistochemical staining with antibodies to collagen type III (brown collagen III fibers).</p></caption><graphic xlink:href="5_2008_Article_44_Fig11" id="MO11"/></fig>
###xml 179 186 <span type="species:ncbi:9606">patient</span>
###xml 611 618 <span type="species:ncbi:9606">patient</span>
###xml 806 813 <span type="species:ncbi:9606">patient</span>
Examples of bronchial mucosal biopsies stained with toluidine blue and antibodies to collagen type III are shown in Figs. 7-11. Fig. 7Photomicrograph of a bronchial biopsy from a patient with long-standing atopic asthma (staining with toluidine blue) showing thickening of the basement membrane and deposition of extracellular matrix below the basement membrane.Fig. 8Photomicrograph of a bronchial biopsy from a healthy subject (staining with toluidine blue) showing epithelium, basement membrane, and a small amount of the subepithelial extracellular matrix.Fig. 9Photomicrograph of a bronchial biopsy from a patient with long-standing atopic asthma showing immunohistochemical staining with antibodies to collagen type III (brown collagen III fibers).Fig. 10Photomicrograph of a bronchial biopsy from a patient with recently diagnosed asthma showing immunohistochemical staining with antibodies to collagen type III (brown collagen III fibers).Fig. 11Photomicrographs of a bronchial biopsy from a healthy subjectc showing immunohistochemical staining with antibodies to collagen type III (brown collagen III fibers).
###end p 47
###begin p 48
###xml 45 52 <span type="species:ncbi:9606">patient</span>
Photomicrograph of a bronchial biopsy from a patient with long-standing atopic asthma (staining with toluidine blue) showing thickening of the basement membrane and deposition of extracellular matrix below the basement membrane.
###end p 48
###begin p 49
Photomicrograph of a bronchial biopsy from a healthy subject (staining with toluidine blue) showing epithelium, basement membrane, and a small amount of the subepithelial extracellular matrix.
###end p 49
###begin p 50
###xml 45 52 <span type="species:ncbi:9606">patient</span>
Photomicrograph of a bronchial biopsy from a patient with long-standing atopic asthma showing immunohistochemical staining with antibodies to collagen type III (brown collagen III fibers).
###end p 50
###begin p 51
###xml 45 52 <span type="species:ncbi:9606">patient</span>
Photomicrograph of a bronchial biopsy from a patient with recently diagnosed asthma showing immunohistochemical staining with antibodies to collagen type III (brown collagen III fibers).
###end p 51
###begin p 52
Photomicrographs of a bronchial biopsy from a healthy subjectc showing immunohistochemical staining with antibodies to collagen type III (brown collagen III fibers).
###end p 52
###begin title 53
Discussion
###end title 53
###begin p 54
###xml 267 269 267 269 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR12">12</xref>
###xml 271 273 271 273 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR27">27</xref>
###xml 275 277 275 277 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR31">31</xref>
###xml 25 33 <span type="species:ncbi:9606">patients</span>
###xml 171 179 <span type="species:ncbi:9606">patients</span>
This study shows that in patients with long-standing asthma, BHR, probably as a result of corticosteroid treatment, is significantly decreased compared with steroid-naive patients with recently diagnosed disease. This is consistent with a number of previous studies [12, 27, 31]. Moreover, significant correlation between steroid therapy duration and PC20 values was found.
###end p 54
###begin p 55
###xml 414 416 414 416 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">10</xref>
###xml 440 442 440 442 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">19</xref>
###xml 623 624 623 624 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">4</xref>
###xml 626 628 626 628 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">14</xref>
###xml 648 649 648 649 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">6</xref>
###xml 1058 1059 1058 1059 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">5</xref>
In the present study we did not find any differences in PC20 values with regard to microscopic or macroscopic features of mucosal inflammation. Our investigation was semiquantitative as we did not count the numbers of inflammatory cells in the mucosa, but it is in keeping with previous studies. The results of other studies on BHR and airway inflammation are largely inconsistent, with equal numbers of positive [10] and negative reports [19]. Our results are consistent with current beliefs that BHR development depends not only on airway inflammation, but also on airway smooth muscle disorders or other unknown agents [4, 14]. Bousquet et al. [6] proposed the hypothesis that in asthmatics, BHR reflects a complex relationship between bronchial inflammation and remodeling, which makes it difficult to demonstrate a simple correlation between these processes and clinical outcome of the disease. In our study we observed a lack of correlation between the degree of BHR and subepithelial collagen III deposition. This is in keeping with previous studies [5].
###end p 55
###begin p 56
###xml 223 224 223 224 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR2">2</xref>
###xml 226 227 226 227 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">9</xref>
###xml 229 231 229 231 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">11</xref>
###xml 233 235 233 235 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">15</xref>
###xml 237 239 237 239 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">17</xref>
It is proven that the "true" basement membrane is of normal structure and thickness in asthmatics. On the other hand, studies comparing asthmatics with normal subjects consistently find thickening of the RBM in asthmatics [2, 9, 11, 15, 17]. There is a wide range of reported values for asthmatics (5.8-30 microm) and control subjects (3.2-7.5 microm). This is probably a matter of the different techniques used.
###end p 56
###begin p 57
###xml 337 339 337 339 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">18</xref>
###xml 341 343 341 343 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR30">30</xref>
The role of RBM thickening in BHR development is not clear and the data are conflicting: thickened RBM might be responsible for excessive BHR and airway obstruction, but there are opinions that increased stiffness of the inner wall of the airway due to a thickened RBM might be a protective mechanism against excessive airway narrowing [18, 30].
###end p 57
###begin p 58
###xml 443 445 443 445 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">17</xref>
###xml 447 449 447 449 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR23">23</xref>
###xml 451 453 451 453 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR25">25</xref>
###xml 875 876 875 876 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">3</xref>
###xml 878 880 878 880 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR13">13</xref>
###xml 882 884 882 884 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR23">23</xref>
###xml 62 70 <span type="species:ncbi:9606">patients</span>
###xml 100 108 <span type="species:ncbi:9606">patients</span>
In the present study we demonstrated thickening of the TBM in patients with asthma, particularly in patients in the LSA group. Significant positive correlation in all asthmatics was found between TBM thickness and asthma duration; however, the corticosteroid therapy applied in the LSA group makes an interpretation of these findings difficult. There are disparities in the previous reports regarding the effects of steroids on RBM thickness [17, 23, 25]. In the present study the effect of corticosteroids on airway remodeling was not directly investigated. We could only indirectly investigate the influence of therapy on clinical and immunohistochemical parameters by observing the steroid-treated group (LSA). Our findings might suggest that corticosteroids could be insufficiently effective in reducing subepithelial fibrosis, which is consistent with previous studies [3, 13, 23], but we cannot exclude the possibility that it could be the result of late treatment introduction.
###end p 58
###begin p 59
###xml 497 498 497 498 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">5</xref>
###xml 530 531 530 531 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">9</xref>
###xml 533 535 533 535 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">10</xref>
###xml 537 539 537 539 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">17</xref>
###xml 147 155 <span type="species:ncbi:9606">patients</span>
In the present study we did not find any correlation between TBM thickness and lung function parameters in asthmatics; however, it was seen in all patients and control subjects combined in one group. It is obvious that for this reason the interpretation of the finding is difficult and it could imply that RBM thickening might not be such an important agent affecting airway obstruction. The lack of association between TBM thickness and BHR demonstrated here is in keeping with previous studies [5], but contradictory to others [9, 10, 17]. Our findings could suggest that both these processes might be independent results of airway inflammation, although one cannot exclude the importance of RBM thickening in BHR development.
###end p 59
###begin p 60
###xml 588 590 588 590 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">11</xref>
###xml 800 802 800 802 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR31">31</xref>
###xml 237 245 <span type="species:ncbi:9606">patients</span>
With regard to subepithelial fibrosis assessment, our findings derived from the collagen III deposition are quite different from those obtained by the assessment of TBM thickness. Collagen III is one of the main components of the RBM in patients with asthma. However, we found no correlation between TBM thickness and collagen III deposition in airway mucosa. The different extents of these two tissue regions could be an explanation, as we investigated collagen III deposition within the RBM and also in the deeper submucosa. Other investigators demonstrated a lack of such association [11]. In the present study we did not find any significant difference in collagen III deposition between the studied groups. Other authors investigated deeper collagen III deposition and obtained similar results [31]. We did not observe any correlation between collagen III deposition and clinical outcome. Considering all the limitations of our study (e.g. small population), our results showing a lack of significant correlation between TBM thickness or collagen III deposition and lung function or BHR could imply that these remodeling components may not be crucial for asthma pathogenesis and clinical outcome.
###end p 60
###begin p 61
###xml 226 227 220 221 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">1</xref>
###xml 299 300 290 291 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">8</xref>
###xml 302 304 293 295 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">17</xref>
###xml 306 308 297 299 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR23">23</xref>
###xml 310 312 301 303 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR30">30</xref>
###xml 330 332 321 323 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR22">22</xref>
###xml 501 503 486 488 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR30">30</xref>
###xml 599 600 581 582 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 734 736 716 718 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">11</xref>
###xml 738 740 720 722 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">17</xref>
###xml 850 851 829 830 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1129 1130 1105 1106 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">8</xref>
###xml 1132 1134 1108 1110 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR21">21</xref>
###xml 1189 1190 1162 1163 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1254 1255 1224 1225 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1352 1353 1319 1320 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1432 1433 1396 1397 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1581 1582 1542 1543 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1770 1771 1728 1729 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1797 1798 1755 1756 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">3</xref>
###xml 1800 1802 1758 1760 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR21">21</xref>
###xml 1804 1806 1762 1764 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR24">24</xref>
TGF-beta is a profibrotic cytokine which reveals the prevailing anti-inflammatory activity. There is a hypothesis of TGF-beta signaling disorders within asthmatic airways which could result in airway inflammation maintenance [1]. The expression of TGF-beta in asthmatics varies among investigators [8, 17, 23, 30]. Magnan et al. [22] reported decreased TGF-beta expression in the asthmatic epithelium, while others (e.g. Vignola) observed elevated TGF-beta expression in the epithelium of asthmatics [30]. In our study we did not find any significant difference in epithelial and submucosal TGF-beta1 expression between the two groups of asthmatics and control subjects. The results of the study confirm those of other investigators [11, 17]. However, it is worth mentioning that we showed an insignificant tendency towards higher epithelial TGF-beta1 expression in healthy subjects compared with asthmatics. There is some evidence that the epithelial TGF-beta distribution might be the main normal source of that growth factor in the airways, where it could play an anti-inflammatory role in maintaining the tissue homeostasis [8, 21]. In the present study the protective role of TGF-beta1 might be confirmed by the positive correlation between TGF-beta1 epithelial immunoreactivity and lung function and the negative correlation between that TGF-beta1 distribution and collagen III deposition. These findings suggest that TGF-beta1 in the epithelium might exert a different role from the one it exerts in the ECM, as these correlations were not seen regarding submucosal TGF-beta1 immunoreactivity. In the present study the other agent making the interpretation difficult could be the corticosteroid therapy introduced in LSA-group, as the influence of ICS on TGF-beta1 expression is not clear [3, 21, 24].
###end p 61
###begin p 62
###xml 829 830 826 827 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 570 578 <span type="species:ncbi:9606">patients</span>
Taking into account all the limitations of our study (e.g. partially semiquantitative methodology), we cannot exclude that airway inflammation and BHR, two major features of asthma, might be loosely related to each other. Obviously, performing cell counts would be necessary to confirm this. Subepithelial fibrosis remains a fact in asthmatic airways, but it role and its linkage with clinical parameters are still unclear and further studies are necessary to explain them as well as the influence of corticosteroid treatment on remodeling components. RBM thickening in patients with asthma is just one of a number of remodeling components, and simple relationships between this parameter and clinical outcome of the disease are difficult to find; however, it is a marker differentiating asthmatics and healthy subjects. TGF-beta1 acts in a complex multidirectional net of mediators. Homeostasis within the net and the cooperation of cytokines or growth factors influences its final result. As we suggest, it can have different activity depending on the distribution and the microenvironment.
###end p 62
###begin title 63
Acknowledgment
###end title 63
###begin p 64
An abstract have been published in Allergy 2007, vol. 62 suppl. 83; p. 140 pos. 369.
###end p 64
###begin title 65
References
###end title 65
###begin article-title 66
Airway inflammation in childhood asthma
###end article-title 66
###begin article-title 67
Airway structural alterations selectively associated with severe asthma
###end article-title 67
###begin article-title 68
Structural changes in airway diseases
###end article-title 68
###begin article-title 69
Mast-cell myositis: a new feature of allergic asthma?
###end article-title 69
###begin article-title 70
Airway hyperresponsiveness, inflammation and subepithelial collagen deposition in recently diagnosed versus long-standing mild asthma
###end article-title 70
###begin article-title 71
Asthma: From bronchoconstriction to airways inflammation and remodeling
###end article-title 71
###begin article-title 72
British Thoracic Society guidelines on diagnostic flexible bronchoscopy
###end article-title 72
###begin article-title 73
Airway remodeling-associated mediators in moderate to severe asthma: effects of steroids on TGF-beta, Il-11, Il-17 and type I and type III collagen expression
###end article-title 73
###begin article-title 74
Airways remodeling is a distinctive feature of asthma and is related to severity of disease
###end article-title 74
###begin article-title 75
Bronchial responsiveness to distilled water and methacholine and its relationship to inflammation and remodeling of the airways in asthma
###end article-title 75
###begin article-title 76
Collagen deposition in large airways may not differentiate severe asthma from milder forms of the disease
###end article-title 76
###begin article-title 77
A dose response of inhaled corticosteroids on bronchial hyperresponsiveness a meta-analysis
###end article-title 77
###begin article-title 78
###xml 20 28 <span type="species:ncbi:9606">children</span>
Difficult asthma in children: an analysis of airway inflammation
###end article-title 78
###begin article-title 79
What evidence implicates airway smooth muscle in the cause of BHR?
###end article-title 79
###begin article-title 80
Epithelial stress and structural remodelling in childhood asthma
###end article-title 80
###begin article-title 81
Epithelial-mesenchymal communication in the pathogenesis of chronic asthma
###end article-title 81
###begin article-title 82
Expression of growth factors and remodelling of the airway wall in bronchial asthma
###end article-title 82
###begin article-title 83
Effects of treatment on airway inflammation and thickening of basement membrane reticular collagen in asthma. A quantitative light and electron microscopic study
###end article-title 83
###begin article-title 84
Bronchial hyperresponsiveness in lung transplant recipients: lack of correlation with airway inflammation
###end article-title 84
###begin article-title 85
The computer assisted histamine bronchoprovocation test
###end article-title 85
###begin article-title 86
Balance between alveolar macrophage Il-6 and TGF-beta in lung transplant recipients
###end article-title 86
###begin article-title 87
Altered compartmentalization of transforming growth factor-beta in asthmatic airways
###end article-title 87
###begin article-title 88
An optimal bronchial tree may be dangerous
###end article-title 88
###begin article-title 89
Therapeutic administration of budesonide ameliorates allergen-induced airway remodelling
###end article-title 89
###begin article-title 90
Relationship of airway wall thickness to airway sensitivity and airway reactivity in asthma
###end article-title 90
###begin article-title 91
Subepithelial fibrosis in the bronchi of asthmatics
###end article-title 91
###begin article-title 92
Structural changes of the airway wall impair respiratory functions, even in mild asthma
###end article-title 92
###begin article-title 93
The bronchitis index: a semiquantitative visual scale for the assessment of airway inflammation
###end article-title 93
###begin article-title 94
Airway remodeling in asthma
###end article-title 94
###begin article-title 95
Transforming growth factor-beta expression in mucosal biopsies in asthma and chronic bronchitis
###end article-title 95
###begin article-title 96
Inter-relationships between airway inflammation, reticular basement membrane thickening and bronchial hyper-reactivity to methacholine in asthma; a systematic bronchoalveolar lavage and airway biopsy analysis
###end article-title 96

